通讯作者: 刘志红, liuzhihong806@163.com

DOI：10.12201/bmr.202605.00075

A Review of Clinical Efficacy and Mechanism of Granulocyte Colony-Stimulating Factor in the Treatment of Recurrent Spontaneous Abortion

• 摘要：复发性流产（recurrent pregnancy loss，RPL）是一种常见的妇产科疾病，影响了女性的身心健康。近年来粒细胞集落刺激因子（granulocyte colony-stimulating factor，G-CSF）作为经典造血生长因子，在RPL治疗中应用日益广泛，引起广大重视。本文将系统阐述G-CSF治疗RPL的作用机制及临床应用现状。G-CSF通过促进血管生成、增加内膜厚度、调控免疫细胞亚群、平衡炎症因子等从而改善子宫内膜容受性、调节母胎免疫耐受。目前临床研究已经证明，G-CSF能降低RPL患者流产率、提高活产率，且给药途径、给药时机及联合治疗方案会影响疗效，比如宫腔内注射优于皮下注射，联合给药或为更优选择、排卵期干预效果更佳。综上，G-CSF是治疗RPL的有效手段，但仍需以大样本、高质量的临床研究来确定个体化精准治疗的最优路径。

  关键词： 复发性流产 粒细胞集落刺激因子 作用机制 临床疗效 富含血小板血浆; ; ; ; 

   

  Abstract: Recurrent pregnancy loss (RPL) is a common gynecological disease that impairs women’s physical and mental health. In recent years, granulocyte colony-stimulating factor (G-CSF), a classic hematopoietic growth factor, has been increasingly widely applied in the treatment of RPL and attracted extensive attention. This article systematically elaborates on the mechanism of action and current clinical application status of G-CSF in the treatment of RPL. G-CSF improves endometrial receptivity and regulates maternal-fetal immune tolerance by promoting angiogenesis, increasing endometrial thickness, regulating immune cell subsets and balancing inflammatory factors. Current clinical studies have confirmed that G-CSF can reduce the miscarriage rate and raise the live birth rate in patients with RPL. Its efficacy is affected by administration routes, timing and combined therapeutic regimens. For instance, intrauterine injection is superior to subcutaneous injection; combined medication tends to be a better option, and intervention during the ovulation period yields more favorable outcomes. In conclusion, G-CSF is an effective therapeutic agent for RPL. Nevertheless, large-sample and high-quality clinical studies are still required to establish the optimal strategies for individualized precise treatment.

  Key words: Recurrent Pregnancy Loss; Granulocyte Colony-Stimulating Factor; Mechanism of Action; Clinical Efficacy; Platelet-Rich Plasma

  提交时间：2026-05-21

  版权声明：作者本人独立拥有该论文的版权，预印本系统仅拥有论文的永久保存权利。任何人未经允许不得重复使用。
• html

• 图表

• 任前军, 李素, 陈雨晴, 陆炜琴, 孟效祖, 赵晓芳, 刘旭东. 粒细胞集落刺激因子治疗肝衰竭的研究进展. 2025. doi: 10.12201/bmr.202505.00003

  蓝清华. 重组人粒细胞-巨噬细胞集落刺激因子联合双歧杆菌治疗化疗后口腔黏膜炎的临床研究. 2025. doi: 10.12201/bmr.202505.00045

  曾碧琪, 吾古力尼散木·艾力, 陈海燕. 维生素D缺乏与复发性流产关系的研究进展. 2026. doi: 10.12201/bmr.202603.00068

  LI YUE. 脂肪血管基质组分联合富血小板纤维蛋白治疗慢性皮肤溃疡的研究进展. 2025. doi: 10.12201/bmr.202510.00022

  史洋溢, 吴勇. 血小板膜糖蛋白抗体的差异性分布对儿童原发免疫性血小板减少症临床疗效影响的研究并文献复习. 2024. doi: 10.12201/bmr.202407.00049

  牟洪林, 陈剑秋. 光动力疗法及复发性呼吸道乳头状瘤病的研究进展. 2024. doi: 10.12201/bmr.202410.00009

  郑秀丽. 重复经颅磁刺激治疗功能性便秘的临床疗效观察. 2025. doi: 10.12201/bmr.202511.00010

  曹邦泰, 林燕. 从“正虚邪伏”探析围绝经期复发性尿路感染的病机与辨治. 2026. doi: 10.12201/bmr.202605.00042

  陈庚, 蒋雯. 血清ALB、CRP、GLB对复发性糖尿病足溃疡的预测价值. 2024. doi: 10.12201/bmr.202410.00061

  马家慧, 王忠. 心力衰竭患者血浆C1q/肿瘤坏死因子相关蛋白6、系统性炎症反应指数水平及临床意义. 2025. doi: 10.12201/bmr.202501.00060

• 序号	提交日期	编号	操作
  1	2026-03-03	10.12201/bmr.202605.00075V1	下载

• 公开评论  匿名评论  仅发给作者 提交评论